Premium
Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells
Author(s) -
Millan Christopher,
Cavalli Emma,
Groth Thomas,
ManiuraWeber Katharina,
ZenobiWong Marcy
Publication year - 2015
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201500102
Subject(s) - chondrogenesis , mesenchymal stem cell , microbiology and biotechnology , glycosaminoglycan , cartilage , extracellular matrix , stem cell , transforming growth factor , cell culture , chemistry , cellular differentiation , matrix (chemical analysis) , biomedical engineering , materials science , biology , anatomy , biochemistry , medicine , genetics , chromatography , gene
A universal method for reproducibly directing stem cell differentiation remains a major challenge for clinical applications involving cell‐based therapies. The standard approach for chondrogenic induction by micromass pellet culture is highly susceptible to interdonor variability. A novel method for the fabrication of condensation‐like engineered microtissues (EMTs) that utilizes hydrophilic polysaccharides to induce cell aggregation is reported here. Chondrogenesis of mesenchymal stem cells (MSCs) in EMTs is significantly enhanced compared to micromass pellets made by centrifugation measured by type II collagen gene expression, dimethylmethylene blue assay, and histology. MSCs from aged donors that fail to differentiate in pellet culture are successfully induced to synthesize cartilage‐specific matrix in EMTs under identical media conditions. Furthermore, the EMT polysaccharides support the loading and release of the chondroinduction factor transforming growth factor β3 (TGF‐β3). TGF‐β‐loaded EMTs (EMT +TGF ) facilitate cartilaginous tissue formation during culture in media not supplemented with the growth factor. The clinical potential of this approach is demonstrated in an explant defect model where EMT +TGF from aged MSCs synthesize de novo tissue containing sulfated glycosaminoglycans and type II collagen in situ.